Rationally designed ruthenium complexes for 1-and 2-photon photodynamic therapy

The use of photodynamic therapy (PDT) against cancer has received increasing attention over recent years. However, the application of the currently approved photosensitizers (PSs) is limited by their poor aqueous solubility, aggregation, photobleaching and slow clearance from the body. To overcome these limitations, there is a need for the development of new classes of PSs with ruthenium(II) polypyridine complexes currently gaining momentum. However, these compounds generally lack significant absorption in the biological spectral window, limiting their application to treat deep-seated or large tumors. To overcome this drawback, ruthenium(II) polypyridine complexes designed in silico with (E,E)-4,4 ' -bisstyryl-2,2 ' -bipyridine ligands show impressive 1- and 2-Photon absorption up to a magnitude higher than the ones published so far. While nontoxic in the dark, these compounds are phototoxic in various 2D monolayer cells, 3D multicellular tumor spheroids and are able to eradicate a multiresistant tumor inside a mouse model upon clinically relevant 1-Photon and 2-Photon excitation. p id=Par Photosensitizers that are stable in biological conditions with absorption in the biological spectral window are needed for photodynamic therapy. Here, the authors report on the development of a Ruthenium complex for 1 and 2-photon therapy to address these issues and demonstrate application in vivo.